Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of ₹63,318 Crore up from ₹57,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to ₹56,009 Crore. Consolidated Net Profit of ₹11,142 up 12% from ₹9,958 Crore in the same quarter of the previous year. The Earnings per Share is ₹66.98 in this quarter.
Dr. Reddy’s Laboratories Limited Q2FY23; Net Profit Increased By 12%
Related Post
- Syngene Q3 FY26 Earnings Results
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO)…
-
Grindwell Norton Q2 FY26 Earnings Results
Grindwell Norton Limited, engaged in manufacturing abrasives, ceramics & plastics and providing IT services, reported…
-
H.G. Infra Q2 FY26 Earnings Results
H.G. Infra Engineering Limited (HGIEL), an Indian road infrastructure company engaged in EPC services, maintenance…